Back

ELCC 2020 - The European Lung Cancer Congress

Apr 15 - Apr 18, 2020 | GenevaSwitzerland

LARVOL is not affiliated with The European Lung Cancer Congress and all trademarks, logos, and brand names are property of their respective owners

Showing 17 abstracts linked to Trials

134P - Characterizing safety of dual immunotherapy, nivolumab (NIVO) + ipilimumab (IPI): understanding and managing select treatment-related adverse events (TRAEs) in CheckMate (CM) 227 Part 1

  • Poster

130O - Characterization of responders to nivolumab (NIVO) + ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC) in CheckMate 227 Part 1

  • Oral